Cell Source, Inc.
CLCS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLCS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLCS
Cell Source, Inc. (CLCS) is a biotechnology company developing cell therapy treatments based on immune tolerance management, currently facing significant financial uncertainty with no revenue and a going concern warning.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2025.
Tracking 1 pipeline candidate for Cell Source, Inc..
Cell Source, Inc. (CLCS) is a biotechnology company developing cell therapy treatments based on immune tolerance management, currently facing significant financial uncertainty with no revenue and a going concern warning.
- Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance [sec_mda · as of 2018-11-14].
- As of March 31, 2025, the company reported cash of $0.0M, net income of -$1.5M, and shareholders' equity of -$15.6M [sec].
- The company has not generated any revenues and has a working capital deficiency; as of June 30, 2024, the working capital deficiency was approximately $17.3 million [sec_mda · as of 2024-08-19].
- Management's plans include continued efforts to raise additional capital through debt and equity financings, but there is no assurance these funds will be sufficient [sec_mda · as of 2026-05-14].
- The company's Veto Cell clinical trial has shown no toxicity, with patients showing successful stem cell engraftment in the absence of severe GvHD [sec_mda · as of 2024-08-19].
What works
- The Veto Cell clinical trial has demonstrated no toxicity and successful stem cell engraftment without severe GvHD, indicating potential for a differentiated cell therapy [sec_mda · as of 2024-08-19].
- The company has a technology platform extensively tested by in vitro studies and confirmed in animal trials, providing a scientific foundation [sec_mda · as of 2018-11-14].
What to weigh
- The company has no revenue, a negative shareholders' equity of -$15.6M as of March 31, 2025, and a working capital deficiency of $17.3M as of June 30, 2024, indicating severe financial distress [sec] [sec_mda · as of 2024-08-19].
- There is substantial doubt about the company's ability to continue as a going concern for at least one year, and operations are funded on a month-to-month basis [sec_mda · as of 2024-07-29].
- Notes payable with principal amounts totaling $5,643,000 and $1,956,000 were past due as of 2024 and through the date of filing, highlighting liquidity pressure [sec_mda · as of 2024-07-29].
- Management acknowledges that if additional financing is not obtained, the company may have to curtail development and could be forced to discontinue operations [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
There is substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date these financial statements are issued.”
SEC MD&A · July 29, 2024
The Veto Cell trial has shown no toxicity and successful engraftment.
“This trial has thus far shown that there has been no toxicity associated with the Veto Cells, with patients consistently showing successful stem cell engraftment, in the absence of severe GvHD.”
SEC MD&A · August 19, 2024
Management plans to raise additional capital but there is no assurance of success.
“Management's plans include continued efforts to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable us to fully complete our development activities or attain profitable operations.”
SEC MD&A · May 14, 2026
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; operations funded month-to-month [sec_mda · as of 2024-07-29].
- Liquidity and capital needs — No revenue, negative equity, and past due notes; reliant on uncertain future financings [sec] [sec_mda · as of 2024-07-29].
- Clinical and regulatory risk — Veto Cell trial is ongoing; no approved products; failure could halt development [sec_mda · as of 2024-08-19].
What to watch
- Ability to secure additional debt or equity financing to continue operations [sec_mda · as of 2026-05-14].
- Progress and results of the Veto Cell clinical trial, including future cohort data [sec_mda · as of 2024-08-19].
- Resolution of past due notes payable and any conversion or extension agreements [sec_mda · as of 2024-07-29].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Cell Source, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cell Source, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
0.0 months
OCF -$600K · Net income -$1M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Cell Source, Inc.?
Cell Source, Inc. (CLCS) is a biotechnology company developing cell therapy treatments based on immune tolerance management, currently facing significant financial uncertainty with no revenue and a going concern warning.
What is Cell Source, Inc.'s lead drug candidate?
Cell Source, Inc.'s most advanced tracked candidate is Veto Cell (Phase 1) for Allogeneic hematopoietic stem cell transplantation (HSCT).
Who is the CEO of Cell Source, Inc.?
Mr. Itamar Shimrat is the chief executive officer of Cell Source, Inc. (CLCS).
Where is Cell Source, Inc. headquartered?
Cell Source, Inc. (CLCS) is headquartered in New York, NY, United States.
What therapeutic areas does Cell Source, Inc. focus on?
Cell Source, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.